Open an account

Viatris

VTRS · NASDAQ

$18.65+$0.39 (+2.14%)TodayMarket closed ·
Prev close $18.26

About VTRS

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 30,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.

Employees
30,000
Headquarters
Canonsburg, Pennsylvania
Listed
Feb 1, 1973
Sector
Health Care
Industry
Pharmaceuticals
Website
viatris.com

VTRS key statistics

Market cap
21.43B
Price-earnings ratio
0.00
Dividend yield
2.60%
Average volume
9.09M
Volume
12.60M
Open price
$18.34
High today
$18.69
Low today
$18.29
52 Week high
$18.67
52 Week low
$9.92

Viatris (VTRS) at a glance

Viatris (VTRS) last traded at $18.65, with a market cap of 21.43B, a price-to-earnings ratio of 0.00 and a dividend yield of 2.60%.

Today the stock has traded between $18.29 and $18.69. The current price is 2.0% above the day's low and 0.2% below its high.

Volume so far is 12.60M shares, above the average of 9.09M shares a day.

Over the past year Viatris has ranged from $9.92 to $18.67, and now sits 100% of the way up that range.

Viatris met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.69 per share against an estimate of $0.6129.

The average analyst price target is $19.99, 7.2% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

78%of 9 analyst ratings say Buy
  • Buy77.8%
  • Hold22.2%
  • Sell0.0%
Price target · 13 analystsAvg $19.99
Low
$13.13
Now
$18.65
High
$26.25

VTRS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 8.1% on average.

  1. Q3 FY24: reported $0.75 per share against an estimate of $0.6897
  2. Q4 FY24: reported $0.54 per share against an estimate of $0.5824
  3. Q1 FY25: reported $0.50 per share against an estimate of $0.4993
  4. Q2 FY25: reported $0.62 per share against an estimate of $0.5669
  5. Q3 FY25: reported $0.67 per share against an estimate of $0.6331
  6. Q4 FY25: reported $0.57 per share against an estimate of $0.5438
  7. Q1 FY26: reported $0.59 per share against an estimate of $0.5123
  8. Q2 FY26: reported $0.69 per share against an estimate of $0.6129

VTRS news

  • Press releasePRNewswire

    Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

  • Press releaseBusiness Wire

    Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

  • Caroline Ryan

    Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy

  • Vandana Singh

    Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout

  • Press releasePRNewswire

    Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

  • Press releasePRNewswire

    Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026

  • Press releasePRNewswire

    Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

  • Avi Kapoor

    Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

Similar companies

Companies in the same industry as Viatris

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.